Shuttle Pharmaceuticals Holdings, Inc.
For the period ended Mar 31, 2025. Filed May 8, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2025 · Filed May 8, 2025
SHPH$5.59+10.8%Stored close · as of Nov 6, 2026
Contents
Item 1. Unaudited Condensed Consolidated Balance Sheets as of March 31, 2025 and December 31, 2024
Shuttle Pharmaceuticals Holdings, Inc.
Condensed Consolidated Balance Sheets
| March 31, | December 31, | |
|---|---|---|
| 2025 | 2024 | |
| Assets | ||
| Current assets | ||
| Cash and cash equivalents | $4,512,607 | $1,920,144 |
| Prepaid expenses | 446,790 | 290,773 |
| Total current assets | 4,959,397 | 2,210,917 |
| Property and equipment, net | 18,356 | 19,364 |
| Deferred financing costs | 71,880 | — |
| Operating lease right-of-use asset | 260,557 | 276,009 |
| Total Assets | 5,310,190 | 2,506,290 |
| Liabilities and Stockholders’ Equity | ||
| Current Liabilities | ||
| Accounts payable and accrued expenses | $896,885 | $596,600 |
| Accrued interest payable - related parties | 1,208 | 1,785 |
| Notes payable to related parties | 128,730 | 190,270 |
| Convertible notes payable, net - fair value option, related parties | 217,379 | 206,085 |
| Convertible notes payable, net - fair value option | 474,749 | 478,120 |
| Operating lease liability | 63,226 | 60,909 |
| Total Current Liabilities | 1,782,177 | 1,533,769 |
| Derivative liability | 22,638 | 25,281 |
| Operating lease liability non-current | 220,110 | 238,088 |
| Total Liabilities | 2,024,925 | 1,797,138 |
| Commitments and contingencies (Note 8) | - | - |
| Stockholders’ Equity | ||
| Series A Convertible Preferred Stock, $0.00001 par value; $1,000 per share liquidation value; 20,000,000 shares authorized; no shares outstanding | — | — |
| Common stock, $0.00001 par value; 100,000,000 shares authorized; 6,382,694 shares issued and outstanding at March 31, 2025; 4,076,567 shares issued and outstanding at December 31, 2024 | 63 | 41 |
| Additional paid in capital | 40,916,310 | 35,287,212 |
| Accumulated deficit | (37,631,108) | (34,578,101) |
| Total Stockholders’ Equity | 3,285,265 | 709,152 |
| Total Liabilities and Stockholders’ Equity | $5,310,190 | $2,506,290 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.